Regulation of tumour necrosis factor production by adrenal hormones in vivo: Insights into the antiinflammatory activity of rolipram

British Journal of Pharmacology

Volumn 117, Issue 7, 1996, Pages 1530-1534

  Pettipher, E R ^a   Labasi, J M ^a   Salter, E D ^a   Stam, E J ^a   Cheng, J B ^a   Griffiths, R J ^a  

^a PFIZER INC   (United States)

Author keywords

Endotoxin; Inflammation; Rolipram; Tumour necrosis factor

Indexed keywords

ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTERONE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GLUCOCORTICOID ANTAGONIST; MIFEPRISTONE; PHOSPHODIESTERASE INHIBITOR; PROPRANOLOL; ROLIPRAM; THIOGLYCOLIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADRENALECTOMY; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CYTOKINE PRODUCTION; HORMONAL REGULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION;

EID: 0029918054     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15317.x     Document Type: Article

References (26)

1. BAILLY, S., FERRURA, B., FAY, M. & GOUGEROT-POCIDALO, M.A. (1990). Differential regulation of IL-6, IL-1α, IL-1β and TNFα production in LPS-stimulated human monocytes: role of cyclic AMP. Cytokine, 2, 205-210.
2. BEAVO, J.A. & REIFSNYDER, D.H. (1990). Primary sequence of cyclic phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol. Sci., 11, 150-155.
3. BERTINI, R., BIANCHI, M. & GHEZZI, P. (1988). Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J. Exp. Med., 167, 1708-1712.
4. BUTLER, L., LAYMAN, N.K., RIEDL, P.E., CAIN, R.L., SHELLHASS, J., EVANS, G.F. & ZUCKERMAN, S.H. (1989). Neuroendocrine regulation of in vivo cytokine production and effects: I. In vivo regulatory networks involving the neuroendocrine system, interleukin 1 and tumor necrosis factor-α. J. Neuroimmunol, 24, 143-153.
5. DENT, G., GIEMBYCZ, M.A., RABE, K.F. & BARNES, P.J. (1991). Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV' - selective PDE inhibitors. Br. J. Pharmacol., 103, 1339-1346.
6. DERKX, B., TAMINIAU, J., RADEMA, S., STRONKHORST, A., WORTEL, C., TYTGAT, G. & VAN DEVENTER, S. (1993). Tumour necrosis factor antibody treatment in Crohn's disease. Lancet, 342,t 173-174.
7. ELLIOTT, M.J., MAINI, R.N., FELDMANN, M., KALDEN, J.R., ANTONI, C., SMOLEN, J.S., LEEB, B., BREEDVELD, F.C., MACFARLANE, J.D., BIJL, H. & WOODY, J.N. (1994). Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet, 344, 1105-1110.
8. FLOWER, R.J., PARENTE, L., PERSICO, P. & SALMON, J.A. (1986). A comparison of the acute inflammatory response in adrenalectomized and sham-operated rats. Br. J. Pharmacol., 87, 57-62.
9. GRISWOLD, D.E., WEBB, E.F., BRETON, J., WHITE, J.R., MARSHALL, P.J. & TORPHY, T.J. (1993). Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation, 17, 333-344.
10. HADLEY, A.J., FLACK, J.D. & BUCKINGHAM, J.C. (1991). Potentiation of cyclic AMP mediated corticotrophin (ACTH) release by denbufylline in vivo and in vitro. Br. J. Pharmacol., 104, 313P.
11. HAWES, A.S., ROCK, C.S., KEOGH, C.V., LOWRY, S.F. & CALVANO, S.E. (1992). In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin. Infect. Immun., 60, 2641-2647.
12. MOLNAR-KIMBER, K.L., YONNO, L., HEASLIP, R.J. & WEICHMAN, B.M. (1992). Differential regulation of TNFα and IL-1β production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors. Media. Inflamm., 1, 411-417.
13. NIELSON, C.P., VESTAL, R.E., STURM, R.J. & HEASLIP, R. (1990). Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol., 86, 801-808.
14. PARANT, M., CONTEL, C.L., PARANT, F. & CHEDID, L. (1991). Influence of endogenous glucocorticoid on endotoxin - induced production of circulating TNFα. Lymphokine Cytokine Res., 10, 265-271.
15. PEACHELL, P.T., UNDEM, B.J., SCHLEIMER, R.P., MACGLASHAN, D.W., LICHTENSTEIN, L.M., CIESLINSKI, L.B. & TORPHY, T.J. (1992). Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol., 148, 2503-2510.
16. PEERS, S.H., MOON, D. & FLOWER, R.J. (1988). Reversal of the antiinflammatory effects of dexamethasone by the glucocorticoid antagonist RU 38486. Biochem. Pharmacol., 37, 556-557.
17. PERRETTI, M., BECHERUCCI, C., SCAPIGLIATI, G. & PARENTE, L. (1989). The effect of adrenalectomy on interleukin 1 release in vitro and in vivo. Br. J. Pharmacol., 98, 1137-1142.
18. PERRETTI, M., DUNCAN, G.S., FLOWER, R.J. & PEERS, S.H. (1993). Serum corticosterone, interleukin 1 and tumour necrosis factor in rat experimental endotoxaemia: comparison between Lewis and Wistar strains. Br. J. Pharmacol., 110, 868-874.
19. PETTIPHER, E.R. & WIMBERLY, D.J. (1994). Cyclooxygenase inhibitors enhance tumour necrosis factor production and mortality in murine endotoxic shock. Cytokine, 6, 500-503.
20. SEKUT, L., YARNALL, D., STIMPSON, S.A., NOEL, L.S., BATEMAN-FITE, R., CLARK, R.L., BRACKEEN, M.F., MENIUS, J.A. & CONNOLLY, K.M. (1995). Antiinflammatory activity of phosphodiesterase(PDE)-IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol., 100, 126-132.
21. SEMMLER, J., WACHTEL, H. & ENDRES, S. (1993). The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol., 15, 409-413.
22. SEVERN, A., RAPSON, N.T., HUNTER, C.A. & LIEW, F.Y. (1992). Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J. Immunol., 148, 3441-3445.
23. SIMPSON, P.J., SCHELM, J.A., SMALLWOOD, J.K., CLAY, M.P. & LINDSTROM, T.D. (1992). Inhibition of granulocyte cAMP - phosphodiesterase by rolipram is not sufficient to protect the canine myocardium from reperfusion injury. J. Card. Pharmacol., 19, 987-995.
24. SOMMER, N., LOSCHMANN, P.A., NORTHOFF, G.H., WELLER, M., STEINBRECHER, A., STEINBACH, J.P., LICHTENFELS, R., MEYERMANN, R., REITHMULLER, A., FONTANA, A., DICHGANS, J. & MARTIN, R. (1995). The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med., 1, 244-248.
25. TURNER, C., ESSER, K.M. & WHEELDON, E.B. (1993). Therapeutic intervention in a rat model of ARDS: IV. Phosphodiesterase IV inhibition. Circ. Shock, 39, 237-245.
26. UNDERWOOD, D.C., MATTHEWS, J.K., OSBORN, R.R., NOVAK, L.B. & TORPHY, T.J. (1992). The significance of β-adrenergic activity on the inhibitory effects of rolipram against early and late phase response to antigen in the guinea pig. Am. Rev. Respir. Dis., 145, A392.